Related Experiment Video
Updated: Jun 1, 2026
07:15
A Mouse Model of Incompletely Resected Soft Tissue Sarcoma for Testing (Neo)adjuvant Therapies
Published on: July 28, 2020
Systematic therapy for unresectable or metastatic soft-tissue sarcomas: past, present, and future
Sherif S Morgan1, Lee D Cranmer
1Melanoma/Sarcoma Research Program, Arizona Cancer Center, University of Arizona, Tucson, AZ, USA.
Current Oncology Reports
|June 3, 2011
Summary
Soft-tissue sarcoma (STS) treatment faces challenges with unresectable or metastatic disease. This review highlights progress and lessons from STS trials, focusing on systemic therapies beyond doxorubicin.
Area of Science:
- Oncology
- Medical Research
- Clinical Trials
Background:
- Unresectable or metastatic soft-tissue sarcoma (STS) affects 40%-60% of patients, with a poor prognosis.
- Doxorubicin is the standard first-line therapy, offering limited response rates of approximately 26%.
- Few effective options exist for patients progressing after initial treatment.
Purpose of the Study:
- To review challenges and progress in soft-tissue sarcoma (STS) treatment over the last 20-25 years.
- To highlight lessons learned from clinical trials in STS.
- To discuss advances in systemic therapies for advanced STS.
Main Methods:
- Literature review of soft-tissue sarcoma (STS) clinical trials published in the last 20-25 years.
- Analysis of treatment outcomes and therapeutic advances.
- Focus on systemic therapies and targeted approaches.
Main Results:
- Doxorubicin remains a cornerstone, but response rates are modest.
- Limited superiority demonstrated by other cytotoxic agents compared to doxorubicin.
- Progress in targeted therapies for specific STS subtypes despite overall heterogeneity.
Conclusions:
- Advances in soft-tissue sarcoma (STS) treatment are challenging due to disease heterogeneity.
- Targeted therapies show promise in specific STS subtypes.
- Continued research and clinical trials are crucial for improving outcomes in advanced STS.
More Related Videos
Related Concept Videos
02:57Targeted Cancer Therapies
The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against specific...
There are several types of targeted therapies against specific...
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:49Cancer Therapies
Cancer therapies are various modes of treatment, such as surgery, radiation therapy, and chemotherapy that are administered to cancer patients.
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
01:27Tumor Immunotherapy
Immunotherapy is a treatment that boosts or manipulates the immune system to fight diseases, including cancer. For instance, by stimulating an immune response through vaccinations against viruses that cause cancers, like hepatitis B virus and human papillomavirus, these diseases can be prevented. Nonetheless, some cancer cells can avoid the immune system due to their rapid mutation and division. The immune response to many cancers involves three phases: elimination, equilibrium, and escape.